RESUMEN
BACKGROUND AND PURPOSE: N-acetyl aspartate (NAA) assessed using proton magnetic resonance spectroscopy (1 H MRS) has a high pathological specificity for axonal density. Retinal nerve fibre layer thickness (RNFLT) measured by using optical coherence tomography is increasingly used as a surrogate marker of neurodegeneration in multiple sclerosis (MS). Our aim was to investigate the relation between RNFLT and NAA/creatine in brain normal-appearing white matter (NAWM), their dynamics over time and the association with clinical outcome measures in relapsing MS. T2 WM lesions served as control tissue. METHODS: Forty-three MS patients underwent standardized neurological examination including the Expanded Disability Status Scale (EDSS), Multiple Sclerosis Functional Composite (MSFC) score, optical coherence tomography and magnetic resonance imaging including 1 H MRS at baseline and after 1 year. RESULTS: At baseline, NAA/creatine level was lower in T2 WM lesions than in NAWM (1.64 ± 0.16 vs. 1.88 ± 0.24, P < 0.001). Lowest levels were found in secondary progressive MS (SPMS). Mean RNFLT was higher in clinically isolated syndrome than in the combined group of relapsing-remitting MS and SPMS (99.8 ± 12.3 µm vs. 92.4 ± 12.8 µm, P = 0.038). In all patients, mean RNFLT decreased by 1.4% during follow-up. At baseline, MSFC z-scores correlated with NAA/creatine levels both in NAWM (r = 0.42; P = 0.008) and T2 WM lesions (r = 0.52, P = 0.004). NAWM NAA/creatine variation correlated with the RNFLT change over 1 year (ρ = 0.43, P = 0.046). CONCLUSIONS: N-acetyl aspartate/creatine level reduction correlated with RNFLT thinning over 1 year in an EDSS stable MS cohort suggesting that these techniques might be sensitive to detect subclinical disease progression.
Asunto(s)
Ácido Aspártico/análogos & derivados , Encéfalo/diagnóstico por imagen , Esclerosis Múltiple/diagnóstico por imagen , Neuronas Retinianas/patología , Sustancia Blanca/diagnóstico por imagen , Adulto , Ácido Aspártico/metabolismo , Axones/metabolismo , Axones/patología , Encéfalo/metabolismo , Encéfalo/patología , Progresión de la Enfermedad , Femenino , Humanos , Estudios Longitudinales , Imagen por Resonancia Magnética/métodos , Espectroscopía de Resonancia Magnética , Masculino , Persona de Mediana Edad , Esclerosis Múltiple/metabolismo , Esclerosis Múltiple/patología , Neuronas Retinianas/metabolismo , Sensibilidad y Especificidad , Tomografía de Coherencia Óptica , Sustancia Blanca/metabolismo , Sustancia Blanca/patologíaRESUMEN
BACKGROUND: Linac output as a function of field sizes has a phantom and a head scatter component. This last term can be measured in-air with appropriate build-up ensuring a complete electron equilibrium and the absence of the contaminant electrons. Equilibrium conditions could be achieved using a build-up cap or a mini-phantom. Monte Carlo simulations in a virtual phantom mimicking a mini-phantom were analysed with the aim of better understanding the setup conditions for measuring the collimator scatter factor that is the head scatter component of the linac output factors. METHODS: Beams of 6 and 15 MV from a TrueBeam, with size from 4 × 4 to 40 × 40 cm2 were simulated in cylindrical acrylic phantoms 20 cm long, of different diameters, from 0.5 to 4 cm, with the cylinder axis coincident with the beam central axis. The PRIMO package, based on PENELOPE Monte Carlo code, was used. The phase-space files for a Varian TrueBeam linac, provided by the linac vendor, were used for the linac head simulation. Depth dose curves were analysed, and collimator scatter factors estimated at different depth in the different phantom conditions. Additionally, in-air measurements using acyrilic and brass build-up caps, as well as acrylic mini-phantom were acquired for 6 and 18 MV beams from a Varian Clinac DHX. RESULTS: The depth dose curves along the cylinders were compared, showing, in each phantom, very similar curves for all analysed field sizes, proving the correctness in estimating the collimator scatter factor in the mini-phantom, provided to position the detector to a sufficient depth to exclude electron contamination. The results were confirmed by the measurements, where the acrylic build-up cap showed to be inadequate to properly estimate the collimator scatter factors, while the mini-phantom and the brass caps gave reasonable measurements. CONCLUSION: A better understanding of the beam characteristics inside a virtual mini-phantom through the analysis of depth dose curves, showed the critical points of using the acrylic build-up cap, and suggested the use of the mini-phantom for the collimator scatter factor measurements in the medium-large field size range.
Asunto(s)
Aceleradores de Partículas/instrumentación , Fantasmas de Imagen , Dispersión de Radiación , Aire , Electrones , Método de Montecarlo , RadiometríaRESUMEN
Screening for surface molecules expressed by metastasizing rat tumors had revealed evidence for metastasis-association of a molecule also expressed on epithelial cells. The similarity to the expression profile of the panepithelial glycoprotein EGP314 prompted us to isolate and sequence the gene and to explore functional features of the molecule in transfected tumor lines. The molecule D5.7A, named according to the antibody, D5.7, used for selection, indeed, is the ortholog of EGP314 with 92% and 80% identity to the murine and the human molecules. Like EGP314, D5.7A has a particular cleavage site, a small cleavage product being resolved under reducing conditions from the membrane anchored part of the molecule. Transfection of a low metastasizing fibrosarcoma, pheochromoblastoma and adenocarcinoma revealed that expression of D5.7A facilitates tumor progression. Depending on the origin of the tumor, D5.7A transfectants either metastasized via the lymphatic system (pheochromoblastoma, adenocarcinoma) or hematogeneously (fibrosarcoma). Particularly after proteolytic cleavage, D5.7A facilitated cell - cell adhesion and provided a proliferative signal upon crosslinking. Thus, the rat ortholog of EGP314 is involved in metastasis formation. Importantly, its functional activities apparently rely on proteolytic cleavage. These findings provide a first evidence on how a panepithelial marker can be involved in tumor progression.
Asunto(s)
Adenocarcinoma/genética , Antígenos de Neoplasias/fisiología , Neoplasias del Colon/genética , Genes , Metástasis de la Neoplasia/genética , Proteínas de Neoplasias/fisiología , Ratas/genética , Adenocarcinoma/patología , Secuencia de Aminoácidos , Animales , Antígenos de Neoplasias/genética , Secuencia de Bases , Células COS , Adhesión Celular , Agregación Celular , División Celular , Movimiento Celular , Clonación Molecular , Neoplasias del Colon/patología , ADN Complementario/genética , Fibrosarcoma/genética , Fibrosarcoma/patología , Regulación Neoplásica de la Expresión Génica , Humanos , Datos de Secuencia Molecular , Proteínas de Neoplasias/genética , Oxidación-Reducción , Neoplasias Pancreáticas/genética , Neoplasias Pancreáticas/patología , Feocromocitoma/genética , Feocromocitoma/patología , Alineación de Secuencia , Homología de Secuencia , Especificidad de la Especie , Organismos Libres de Patógenos Específicos , Transfección , Células Tumorales CultivadasRESUMEN
We have previously described a rat metastasis-associated molecule, C4.4A, which has some common features with the uPAR. Because of its restricted expression in non-transformed tissues a search for the human homologue became of interest. Human C4.4A was cloned from a placental cDNA library. As in the rat, the human uPAR and the human C4.4A genes appear to belong to the same family. Both genes are located on chromosome 19q13.1-q13.2 and both molecules have a glycolipid anchor site and are composed of three extracellular domains. Only domains one and two of the human C4.4A and the uPAR protein show a significant degree of identity. Expression of the human C4.4A was observed by RT-PCR and Northern blotting in placental tissue, skin, esophagus and peripheral blood leukocytes, but not in brain, lung, liver, kidney, stomach, colon and lymphoid organs. Yet, tumors derived from the latter tissues frequently contained C4.4A mRNA. As demonstrated for malignant melanoma, C4.4A mRNA expression correlated with tumor progression. While nevi were negative and only a minority of primary malignant melanoma expressed C4.4A, all metastases were C4.4A-positive. Taking into account the high degree of homology between rat and human C4.4A, the conformity of the expression profiles and the association of rat C4.4A with tumor progression, human C4.4A might well become a prognostic marker and possibly a target of therapy.
Asunto(s)
Anticuerpos Monoclonales/genética , Regulación Neoplásica de la Expresión Génica , Secuencia de Aminoácidos , Animales , Anticuerpos Monoclonales/metabolismo , Clonación Molecular , ADN Complementario , Femenino , Humanos , Neoplasias Pulmonares/genética , Neoplasias Pulmonares/secundario , Datos de Secuencia Molecular , Metástasis de la Neoplasia/genética , Metástasis de la Neoplasia/inmunología , Placenta/fisiología , Embarazo , Ratas , Receptores de Superficie Celular/genética , Receptores del Activador de Plasminógeno Tipo Uroquinasa , Homología de Secuencia de Aminoácido , Células Tumorales CultivadasAsunto(s)
Ventrículos Cardíacos/efectos de los fármacos , Inmunosupresores/efectos adversos , Mitoxantrona/efectos adversos , Esclerosis Múltiple/tratamiento farmacológico , Adulto , Diástole , Electrocardiografía , Femenino , Ventrículos Cardíacos/patología , Humanos , Inmunosupresores/uso terapéutico , Masculino , Mitoxantrona/uso terapéutico , Volumen SistólicoRESUMEN
BACKGROUND: Chronic cerebrospinal venous insufficiency (CCSVI) was proposed as the causal trigger for developing multiple sclerosis (MS). However, current data are contradictory and a gold standard for venous flow assessment is missing. OBJECTIVE: To compare structural magnetic resonance venography (MRV) and dynamic extracranial color-coded duplex sonography (ECCS) in a cohort of patients with MS. METHODS: We enrolled 40 patients (44 ± 10 years). All underwent contrast-enhanced MRV for assessment of internal jugular vein (IJV) and azygos vein (AV) narrowing, graded into 3 groups: 0%-50%, 51%-80%, and >80%. ECCS analysis of blood flow direction, cross-sectional area (CSA), and blood volume flow (BVF) in both IJV and vertebral veins (VV) occurred in the supine and upright body position. RESULTS: MRV identified 1 AV narrowing. IJV analysis yielded 12 patients for group 1 (30%), 19 patients for group 2 (48%), and 9 patients for group 3 (22%). By ECCS criteria, 4 patients (10%) presented with venous drainage abnormalities. Jugular BVF was different only between groups 1 and 3 (616 ± 133 vs. 381 ± 213 mL/min, p = 0.02). No other parameters in supine position and none of the parameters in the upright body position, apart from the IJV-BVF decrease in groups 1 and 3 (479 ± 172 vs. 231 ± 144 mL/min, p = 0.01), were different. CONCLUSIONS: Our ECCS data contradict the postulated 100% prevalence of CCSVI criteria in MS. MRV seems more sensitive to detect IJV narrowing compared to ECCS. A measurable hemodynamic effect only exists in vessel narrowings >80%. Our combined data argue against a causal relationship of venous narrowing and MS, favoring the rejection of the CCSVI hypothesis.
Asunto(s)
Imagen por Resonancia Magnética , Esclerosis Múltiple/diagnóstico por imagen , Esclerosis Múltiple/patología , Ultrasonografía Doppler en Color , Insuficiencia Venosa/diagnóstico por imagen , Insuficiencia Venosa/patología , Adulto , Estudios Transversales , Femenino , Humanos , Venas Yugulares/diagnóstico por imagen , Venas Yugulares/patología , Masculino , Persona de Mediana Edad , Flebografía , Proyectos PilotoRESUMEN
Mitoxantrone is an anthracenedione antineoplastic agent approved as an escalating immunotherapy for multiple sclerosis. Owing to structural similarity with other anthracyclines, cardiotoxicity is a severe side effect of mitoxantrone. The risk of mitoxantrone-induced cardiotoxicity in patients with multiple sclerosis increases with cumulative doses >100 mg/m(2) body surface area (BSA). However, the effect of mitoxantrone on cardiac function in the early phase of treatment with cumulative doses <100 mg/m(2) BSA is unclear. The present report concerns four patients with a temporary and considerable decrease in left ventricular ejection fraction (LVEF) and with additional echocardiographic findings of diastolic dysfunction after only one or two doses of mitoxantrone. The risk of cardiotoxicity at low doses of mitoxantrone is highlighted.
RESUMEN
In a dental-psychological investigation 100 young adults, aged 18-25, characterized by different courses of education, were subject to a standardized interview, action oriented diagnostics and dental examination. Knowledge, behaviour as well as state of oral health were different and in all did not come up to our expectations; but there were some correlations. It is indicated to optimize knowledge, behaviour and state of oral health by means of individual and collective measures taking educational specifics into consideration.